Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Cisplatin ototoxicity affecting cochlear implant benefit. Otol Neurotol 2011 Aug;32(6):969-72

Date

07/07/2011

Pubmed ID

21730884

Pubmed Central ID

PMC3144856

DOI

10.1097/MAO.0b013e3182255893

Scopus ID

2-s2.0-80051786515 (requires institutional sign-in at Scopus site)   10 Citations

Abstract

OBJECTIVE: Report a case of loss of cochlear implant benefit after cisplatin therapy to treat osteosarcoma. Examine the implications for the loci of cisplatin-associated cochleotoxicity.

STUDY DESIGN: Retrospective case review.

SETTING: Tertiary referral center.

PATIENTS: Single case study.

INTERVENTION(S): None.

MAIN OUTCOME MEASURE(S): Cochlear implant programming levels.

RESULTS: Increase in cochlear implant programming T- and C-levels after cisplatin therapy.

CONCLUSION: Cisplatin therapy likely affects spiral ganglion cells. It seems that auditory cells other than outer hair cells in the organ of Corti are affected by cisplatin because the hearing sensitivity of this patient with nonfunctioning outer hair cells declined after receiving chemotherapy. Implications of these findings are discussed.

Author List

Harris MS, Gilbert JL, Lormore KA, Musunuru SA, Fritsch MH

Author

Michael S. Harris MD Associate Professor in the Otolaryngology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Antineoplastic Agents
Cisplatin
Cochlear Implantation
Cochlear Implants
Femoral Neoplasms
Hearing Loss, Sensorineural
Humans
Male
Osteosarcoma
Speech Perception